Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 16th 2015

Bim Expression Could Predict Patient Response to PD-1 Blockade, Mayo Clinic Study Finds

Surabhi Dangi-Garimella, PhD

Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.

September 16th 2015

Participating Faculty: Management of Advanced/Metastatic Melanoma: New and Emerging Treatment Pathways, Therapies, and Challenges [CPE]

September 15th 2015

Cancer Drugs Driving 340B Growth Even More Than Understood, Report Finds

Mary K. Caffrey

The report, commissioned by the Community Oncology Alliance, finds that Medicare Part B cancer drug spending rose 123% in 340B hospitals from 2010 to 2013, but only 31% in non-340B hospitals; it fell 5% in community practices in the same period.

September 15th 2015

Interoperability Important for Better Outcomes: ASCO to Congress

The American Society of Clinical Oncology has urged Congress to recognize the impact of barriers to interoperability of electronic health records on patient outcomes.

September 15th 2015

In Conversation With an Oncologist: 340B and Its Impact on the Community

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.

September 14th 2015

Demographic Factors Influence Survival in Younger Patients With Leukemia

Surabhi Dangi-Garimella, PhD

The study, published in the journal Cancer, found that non-biological factors are as important as biological variables in shaping outcomes in young patients with leukemia.

Dr Peter Bach Explains How Increasing Drug Prices Stifle Innovation

September 14th 2015

Dr Peter Bach Explains How Increasing Drug Prices Stifle Innovation

The ability to charge increasingly higher prices for drugs that already have competition on the market is stifling innovation and wasting resources and human subjects, according to Peter Bach, MD, MAPP, director of Memorial Sloan Kettering Cancer Center's Center for Health Policy and Outcomes.

September 14th 2015

California "Aid-in-Dying" Bill Awaits Governor's Decision

Mary K. Caffrey

Supporters say the bill would bring choice and dignity to those suffering, while opponents say the poor will be pressured by family members and heirs to take their lives because healthcare is too expensive.

September 14th 2015

Care Access, Centers of Excellence, and the ACA: Expert Interchange at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD

Healthcare policy experts gathered in Washington, DC, to discuss access, cost, and the definition of value in oncology care.

Dr Joseph Alvarnas Addresses Rising Medical Costs

September 13th 2015

Dr Joseph Alvarnas Addresses Rising Medical Costs

Healthcare practitioners are well aware that the rising cost of medical advances may affect their ability to deliver great care to all their patients, but there are ways they can address the issue, said Joseph Alvarnas, MD, the editor-in-chief of Evidence-Based Oncology.

September 11th 2015

Immune Treatments in Cancer Need Additional Vigilance and Earlier Recognition

Surabhi Dangi-Garimella, PhD

An abstract presented at the 16th World Conference on Lung Cancer presented results from a study that monitored irAEs resulting from treatment with immune checkpoint inhibitors.

September 10th 2015

Study Identifies Actionable Mutations in Young Lung Cancer Patients

Surabhi Dangi-Garimella, PhD

Presented at the ongoing World Conference on Lung Cancer, the trial has identified 7 actionable genomic alterations in lung cancer patients under 40 years of age.

Kim Thiboldeaux Explains Patient Misconceptions of Cancer Clinical Trials

September 10th 2015

Kim Thiboldeaux Explains Patient Misconceptions of Cancer Clinical Trials

Kim Thiboldeaux, chief executive officer of the Cancer Support Community, discusses the importance of providing strong community support, the misconceptions of clinical trials, and creating a tailored care plan.

September 10th 2015

ASCO Submits Comments on the Proposed Medicare Physician Fee Schedule Rules

Surabhi Dangi-Garimella, PhD

At the end of CMS' comment period, the American Society of Clinical Oncology submitted its comments and recommendations for the proposed changes.

September 9th 2015

CalPERS Successfully Implemented Reference Payment to Save on Colonoscopy Costs

Surabhi Dangi-Garimella, PhD

The California Public Employees' Retirement System saved $7 million on screening colonoscopies during a 2-year period following implementation of reference pricing.

September 9th 2015

FDA Grants Priority Review for Alectinib in Advanced NSCLC Resistant to Crizotinib

Surabhi Dangi-Garimella, PhD

The drug, approved in Japan last year, had been granted Breakthrough Therapy designation by the FDA.

September 8th 2015

Preliminary Results Promising for Opdivo-Yervoy as First-Line in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

With a new dosing schedule, low toxicity and a PD-L1 expression-driven response was observed.

September 8th 2015

CMS Changes to Physician Fee Schedule Face Resistance From Radiation Oncologists

Surabhi Dangi-Garimella, PhD

With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.

September 7th 2015

CVS: Taking Tobacco From Stores Prompted Quit Attempts; Sales of Cigarettes Dropped

Mary K. Caffrey

Data in study show removal of tobacco from stores led to surge in purchase of nicotine patches.

September 7th 2015

Keytruda Gains NICE Approval While Kadcyla Fails

Surabhi Dangi-Garimella, PhD

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

Dr Amy Davidoff Examines Factors Influencing Patient Treatment Decisions in Cancer Care

September 7th 2015

Dr Amy Davidoff Examines Factors Influencing Patient Treatment Decisions in Cancer Care

For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health

September 7th 2015

Watch and Wait Feasible in Nearly 70% of Men With Prostate Cancer, Study Suggests

Surabhi Dangi-Garimella, PhD

Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.

Dr Robert Dubois Outlines the Creation, Utilization of Clinical Pathways

September 6th 2015

Dr Robert Dubois Outlines the Creation, Utilization of Clinical Pathways

A survey of groups using and developing clinical pathways revealed 7 distinct themes that highlight how these pathways are created and used, and the challenges and barriers to creating new pathways, explained Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.

September 4th 2015

Integrating Genomics into Pediatric Cancer Care

Surabhi Dangi-Garimella, PhD

Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.

September 3rd 2015

Long-Anticipated Biosimilar From Novartis Launched, but at What Price?

Surabhi Dangi-Garimella, PhD

Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.

September 3rd 2015

Prophylactic Breast Surgery on the Rise in Men With Breast Cancer

Surabhi Dangi-Garimella, PhD

Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.

September 2nd 2015

Telehealth Intervention Can Overcome Barriers to Colorectal Screening

Surabhi Dangi-Garimella, PhD

Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.

September 2nd 2015

Rolapitant Gains FDA Approval for CINV

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

September 1st 2015

ASCO Publishes Policy Update on Genomic Testing for Cancer Susceptibility

Surabhi Dangi-Garimella, PhD

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

Mary Lou Smith on Ensuring Patients' Voices Are Heard

September 1st 2015

Mary Lou Smith on Ensuring Patients' Voices Are Heard

Sometimes patients are so concerned with being good patients that they simply agree to what the clinician has said without fully understanding, and it's important to ask questions and ensure their voices are heard, said Mary Lou Smith, MBA, co-founder of the Research Advocacy Network.

...

121 122 123 124 125 126 127 128 129

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions